Welcome to our dedicated page for SAB BIOTHERAPEUTICS news (Ticker: SABSW), a resource for investors and traders seeking the latest updates and insights on SAB BIOTHERAPEUTICS stock.
SAB Biotherapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a portfolio of products from its proprietary immunotherapy platform to produce targeted human polyclonal antibodies. The company leverages transchromosomic cattle genetically designed to produce human antibodies in response to an antigen. With a breakthrough therapy designation from the FDA, SAB-176 targets influenza strains, demonstrating sustained neutralization activity. The company's DiversitAb platform enables the production of fully human target-specific biologics for various therapeutic areas.
Rhea-AI Summary
SAB Biotherapeutics, Inc. (SABS) collaborates with Navy Medical Research Command for a safety study on SAB-176, a therapy for influenza prevention. The study aims to evaluate the safety and tolerability of intramuscular administration of SAB-176, a novel multi-target biologic with sustained neutralization activity against Influenza A and B. The partnership, funded by the Henry Jackson Foundation, utilizes SAB's DiversitAb™ platform to develop fully human polyclonal antibodies. SAB-176 has received Breakthrough Therapy and Fast Track Designations from the FDA. The study marks the first intramuscular administration of a DiversitAb™ platform product, showcasing the potential of SAB's therapeutic products beyond type 1 diabetes treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
SAB Biotherapeutics, Inc. (SABS) announced Samuel J. Reich will present at the BIO CEO & Investor Conference to discuss the latest developments in their lead clinical program, SAB-142, for delaying Type 1 diabetes onset and progression.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
News
Rhea-AI Summary
SAB Biotherapeutics, Inc. (SABS) will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference to discuss the latest developments from its lead clinical program, SAB-142, a novel biologic for delaying onset and progression of Type 1 diabetes in adults and children.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
SAB Biotherapeutics, Inc. announced the appointment of Samuel J. Reich as the new CEO, effective February 2, 2024. Eddie J. Sullivan, Ph.D., will continue as President and a member of the Board of Directors. The company aims to progress its lead product candidate SAB-142 through milestones towards approval, with a focus on delaying the onset or progression of type 1 diabetes (T1D).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
SAB Biotherapeutics, Inc. (SABS) has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) after conducting a 1-for-10 reverse split of its common shares. The Company's common shares were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, which was achieved on January 23, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
SAB Biotherapeutics, Inc. (Nasdaq: SABS) announced a reverse stock split of its outstanding shares of common stock, effective January 5, 2024, to increase per share trading price and maintain Nasdaq listing compliance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
SAB Biotherapeutics, Inc. (Nasdaq: SABS) has initiated the first-in-man Phase 1 clinical study of SAB-142, a fully-human anti-thymocyte immunoglobulin (ATG) targeting immune cells involved in the destruction of insulin-producing pancreatic beta cells to potentially preserve beta cell function. The company is pursuing IND and CTA filings with U.S. FDA and EMA in 2024 to advance SAB-142 into a Phase 2b study for disease-modification of Type 1 Diabetes (T1D). The Phase 1 trial in Australia aims to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of SAB-142 in healthy volunteers and participants with T1D, with a focus on establishing Proof of Biological Activity (POBA) for SAB-142.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
SAB Biotherapeutics (Nasdaq: SABS) announced the appointment of Katie Ellias to the Company’s Board of Directors. Ms. Ellias, a Managing Director at the JDRF T1D Fund LLC, brings extensive experience in T1D-oriented therapies. With approximately $200 million in assets, the T1D Fund has invested in SAB. Ms. Ellias' expertise and impact are expected to benefit SAB as it aims to change the T1D treatment paradigm.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
SAB Biotherapeutics, Inc. (NASDAQ: SABS) announced the funding of the second tranche of a previously-announced financing, raising total aggregate proceeds to date of $67.1 million. The funds will support the development of SAB-142, a potential disease-modifying therapy for type 1 diabetes and other autoimmune conditions. Participating investors include Sessa Capital, BVF Partners, RTW Investments, Marshall Wace, ATW, and the JDRF T1D Fund. The investment will move human trials forward for SAB’s lead research program, which was recently granted approval by Australian authorities to begin a first-in-human Phase 1 clinical study of SAB-142.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
SAB Biotherapeutics, Inc. (Nasdaq: SABS) has raised a combined $67.1M in a private placement and Tranche warrant exercise with a syndicate of leading investors. The company also received approval from the Human Research Ethics Committee (HREC) to commence a First-in-Human Phase 1 clinical trial investigating SAB-142 in Australia. Additionally, Michael G. King Jr. has been appointed as the new Chief Financial Officer. The company reported financial results for the third quarter of 2023 and provided a company update, highlighting the advancement of SAB-142, their T1D immunotherapy, and the addition of senior expertise to the team.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of SAB BIOTHERAPEUTICS (SABSW)?
The current stock price of SAB BIOTHERAPEUTICS (SABSW) is $0.03 as of February 25, 2025.
What is SAB Biotherapeutics Inc. focused on?
SAB is focused on developing and commercializing a portfolio of products from its immunotherapy platform to produce human polyclonal antibodies.
What is the novel DiversitAb platform used by SAB?
The DiversitAb platform enables the rapid production of targeted human polyclonal antibodies using transchromosomic cattle.
What is SAB-176 and its significance?
SAB-176 is a biologic targeting influenza strains with sustained neutralization activity and has received FDA Breakthrough Therapy Designation.
What is the focus of SAB's clinical programs?
SAB focuses on disease-modifying therapeutic approaches, such as SAB-142 targeting type 1 diabetes, aiming to prevent disease progression.
What are some key achievements of SAB in the clinical trials?
SAB has completed Phase 2 studies demonstrating the efficacy of its products in challenging influenza models, paving the way for potential breakthrough treatments.
How does SAB's immunotherapy platform differ from traditional methods?
SAB's platform leverages transchromosomic cattle to produce fully human antibodies, eliminating the need for convalescent plasma or human donors.
What is the significance of SAB's approach to human-specific biologics?
SAB's approach allows the production of highly targeted, high-potency, fully human IgGs to address serious unmet needs in various human diseases.
How does SAB aim to contribute to the field of immunotherapy?
SAB is committed to pioneering disease-modifying therapies, focusing on advancing treatments for immune and autoimmune disorders like type 1 diabetes.
How does SAB prioritize research and development efforts?
SAB's research and development efforts are geared towards developing safe, effective therapies with differentiated safety and immunogenicity profiles, aiming to change treatment paradigms in various diseases.
What future milestones can we expect from SAB?
SAB is on track to achieve upcoming milestones, including a Phase 2B trial for its lead candidate, SAB-142, and continued advancements in pioneering disease-modifying therapies.
SAB BIOTHERAPEUTICS INC